ATE333645T1 - Peptide und zusammensetzungen, die die apoptose modulieren. - Google Patents

Peptide und zusammensetzungen, die die apoptose modulieren.

Info

Publication number
ATE333645T1
ATE333645T1 AT96913307T AT96913307T ATE333645T1 AT E333645 T1 ATE333645 T1 AT E333645T1 AT 96913307 T AT96913307 T AT 96913307T AT 96913307 T AT96913307 T AT 96913307T AT E333645 T1 ATE333645 T1 AT E333645T1
Authority
AT
Austria
Prior art keywords
compositions
domain
peptides
bak
directed
Prior art date
Application number
AT96913307T
Other languages
English (en)
Inventor
Thomas D Chittenden
Robert J Lutz
Original Assignee
Apoptosis Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apoptosis Technology Inc filed Critical Apoptosis Technology Inc
Application granted granted Critical
Publication of ATE333645T1 publication Critical patent/ATE333645T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96913307T 1995-05-12 1996-05-06 Peptide und zusammensetzungen, die die apoptose modulieren. ATE333645T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/440,391 US5656725A (en) 1995-05-12 1995-05-12 Peptides and compositions which modulate apoptosis

Publications (1)

Publication Number Publication Date
ATE333645T1 true ATE333645T1 (de) 2006-08-15

Family

ID=23748576

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913307T ATE333645T1 (de) 1995-05-12 1996-05-06 Peptide und zusammensetzungen, die die apoptose modulieren.

Country Status (10)

Country Link
US (3) US5656725A (de)
EP (1) EP0835447B1 (de)
JP (1) JPH11506907A (de)
AT (1) ATE333645T1 (de)
CA (1) CA2220753C (de)
DE (1) DE69636365T2 (de)
DK (1) DK0835447T3 (de)
ES (1) ES2268704T3 (de)
PT (1) PT835447E (de)
WO (1) WO1996035951A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015084A1 (en) 1993-11-30 1995-06-08 Lxr Biotechnology Inc. Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
US6221615B1 (en) * 1995-05-12 2001-04-24 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
AU6679498A (en) * 1997-03-20 1998-10-12 Lxr Biotechnology Inc. A novel bak binding protein, dna encoding the protein, and methods of use thereof
WO1998058541A1 (en) * 1997-06-24 1998-12-30 Dana-Farber Cancer Institute, Inc. Modulation of apoptosis
US6544972B1 (en) 1997-09-25 2003-04-08 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
WO1999016787A1 (en) * 1997-09-26 1999-04-08 Washington University Cell death agonists
US6165732A (en) * 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6720311B2 (en) 1997-12-18 2004-04-13 David Tsai Polypeptide for the treatment of cancer and a method for preparation thereof
US6737402B2 (en) 1997-12-18 2004-05-18 David Tsai Method of preparing fetuin to induce apoptosis
US7238662B2 (en) * 1997-12-18 2007-07-03 Ambryx Biotechnology, Inc. Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6190912B1 (en) * 1998-03-31 2001-02-20 Thomas Jefferson University Blk genes and uses thereof in apoptosis
EP1080233A4 (de) * 1998-05-18 2003-02-05 Apoptosis Technology Inc Verbindungen, untersuchungsverfahren und verwendungen die anti-apoptotische gene und genprodukte beinhalten
US6218511B1 (en) 1998-05-18 2001-04-17 Apoptosis Technology, Inc. Anti-apoptotic genes of human cytomegalovirus (HCMV) and their use
EP1189939A1 (de) * 1999-06-25 2002-03-27 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Bh3-modifizierte peptide
KR20020059639A (ko) * 1999-10-22 2002-07-13 이곤 이 버그 Ｂｃｌ-ｘＬ과 상호작용하는 폴리펩타이드인 Ｐａｂｌｏ및 이와 관련된 용도
US20040157327A1 (en) * 1999-10-22 2004-08-12 Wyeth Pablo, a polypeptide that interacts with BCL-XL, and uses related thereto
US7495070B2 (en) * 2000-04-24 2009-02-24 Yale University Protein binding miniature proteins
US7297762B2 (en) * 2000-04-24 2007-11-20 Yale University Modified avian pancreatic polypeptide miniature binding proteins
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US20040043949A1 (en) * 2002-08-30 2004-03-04 Christopher Richardson Therapeutic system targeting pathogen proteases and uses thereof
KR20050103185A (ko) * 2002-11-07 2005-10-27 리전츠 오브 더 유니버스티 오브 미네소타 출혈과 관련된 신경계 손상의 치료 방법
US20060204481A1 (en) * 2003-04-02 2006-09-14 Steer Clifford J Methods of promoting cell viability
WO2006034454A1 (en) * 2004-09-23 2006-03-30 The Trustees Of The University Of Princeton Bcl-2 family member and bh-3 only proteins for use in development of peptidomimetics
JP2008530100A (ja) * 2005-02-10 2008-08-07 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 視覚障害の治療方法
US20090253771A1 (en) * 2006-05-08 2009-10-08 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V Inhibition of gliotoxin
US7790184B2 (en) * 2006-08-01 2010-09-07 Washington University In St. Louis Cytochrome c synthesis inhibitors
US20100273722A1 (en) * 2007-08-06 2010-10-28 Yale University Modified miniature proteins
WO2012080548A1 (es) * 2010-12-17 2012-06-21 Consejo Superior De Investigaciones Científicas (Csic) Mutante de bak, método asociado para la identificación de sustancias moduladoras de bak y péptido inhibidor de la actividad bak

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6221615B1 (en) * 1995-05-12 2001-04-24 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis

Also Published As

Publication number Publication date
US5656725A (en) 1997-08-12
DE69636365T2 (de) 2007-08-02
CA2220753A1 (en) 1996-11-14
EP0835447A4 (de) 1999-06-02
DK0835447T3 (da) 2006-11-20
CA2220753C (en) 2010-12-21
US20090081705A1 (en) 2009-03-26
US5863795A (en) 1999-01-26
DE69636365D1 (de) 2006-08-31
WO1996035951A1 (en) 1996-11-14
JPH11506907A (ja) 1999-06-22
PT835447E (pt) 2006-12-29
EP0835447A1 (de) 1998-04-15
EP0835447B1 (de) 2006-07-19
ES2268704T3 (es) 2007-03-16

Similar Documents

Publication Publication Date Title
ATE333645T1 (de) Peptide und zusammensetzungen, die die apoptose modulieren.
EA199900808A1 (ru) Бифенилсульфонамиды и их производные, модулирующие активность эндотелина
BR9814611A (pt) Polipeptìdeos modificados dependentes de vitamina k
DE69818450D1 (de) Im wesentlichen reines zonulin als physiologischer modulator von "tight junctions" bei säugern
NO20061455L (no) 2,6 dioksopiperidin samt farmasoytiske preparater som inneholder disse
ES2089822T3 (es) Polimeros para productos cosmeticos y de cuidado personal.
DE69723730D1 (de) Pharmazeutische zusammensetzungen, die alkylamide von di- und tricarbonsäuren als gelierungsmittel enthalten
ATE217754T1 (de) Verwendung von aerogelen in der landwirtschaft
DE69713287D1 (de) Verbindungen von wirkstoffen, welche klopidogrel und antithrombotische mittel enthalten
DE69326016D1 (de) Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen
NO953643D0 (no) Nytt middel til kontroll av celleaktivitet
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
DE69738930D1 (de) Methoden zur modulation der melaninsynthese
DE69432055D1 (de) Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht
BG103096A (en) Thrombin inhibitors
MX9302931A (es) Nuevas 4-aza-5&-colestan-onas 7b-substituidas como inhibidores de 5&-reductasa.
BR9913190A (pt) Modulação de proteìnas quinase de linhagemmúltipla
FR2681784B1 (fr) Composition dermatologique et/ou cosmetologique contenant des retinouides et utilisation de nouveaux retinouides.
DE59610633D1 (de) Medikament, insbesondere zur modulation der immunantwort bei der bekämpfung von viren, tumoren, bakterien und parasiten
DE69311541D1 (de) Kosmetische oder pharmazeutische zusammensetzungen zur topischen anwendung die deacylierten glycerophospholipide enthalten
DE69510545D1 (de) Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
MXPA02008453A (es) Metodos para modular selectivamente rutas de apoptosis survivin.
ATE302215T1 (de) Modulatoren von intrazellulären entzündungs-, zelltod- und zellüberlebenswegen, die card- und kinase-domänen enthalten
BR9806193A (pt) Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm
MXPA02007787A (es) Moleculas trade y uso relacionado con las mismas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0835447

Country of ref document: EP